摘要
新型冠状病毒(SARS-CoV-2)传染性强,可引起新型冠状病毒肺炎(COVID-19)。抗SARSCoV-2抗体安全性高,特异性强,中和SARS-CoV-2的能力显著,被认为是治疗COVID-19的理想药物。鉴于SARS-CoV-2突起蛋白(S蛋白)的核心地位,目前开发的抗SARS-CoV-2抗体基本以S蛋白为靶点,识别表位多位于受体结合域,少数位于S2亚基或S1/S2蛋白水解位点。利用单细胞测序、抗体库和转基因小鼠等技术,多抗(外周血来源)、单抗、抗体融合蛋白和单域抗体等均取得了明显进展,多个品种已进入临床试验,某些品种已获得美国FDA紧急使用授权。本文综述SARS-CoV-2中和抗体的研究进展,为COVID-19疫情防控提供参考。
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is so contagious that it has caused a global pandemic known as COVID-19.Anti-SARS-CoV-2 antibodies are safe and specific,and have satisfactory neutralizing activities against the virus.As the spike glycoprotein(S protein)of SARS-CoV-2 is critical to virus infection,it is the most important target of neutralizing antibodies.Most of their epitopes are located in the receptor binding domain,while others are located in S2 subunit or S1/S2 hydrolysis site.Serum-derived polyclonal antibodies,monoclonal antibodies,Fc fusion proteins and signle-domain antibodies can be screened out using single-cell sequencing,antibody library,and transgenic mice technologies.A number of antibodies have entered clinical trials,some of which have been authorized by US Food and Drug Administration for emergency use.Here the current develop⁃ments of anti-SARS-CoV-2 neutralizing antibodies are reviewed,which will be of benefit to COVID-19 treatment.
作者
乔春霞
王晶
罗龙龙
冯健男
QIAO Chun-xia;WANG Jing;LUO Long-long;FENG Jian-nan(Institute of Pharmacology and Toxicology,Academy of Military Medical Sciences,Beijing 100850,China)
出处
《中国药理学与毒理学杂志》
CAS
北大核心
2021年第7期481-492,共12页
Chinese Journal of Pharmacology and Toxicology
基金
国家自然科学基金(31771010)。
关键词
新型冠状病毒
新型冠状病毒肺炎
中和抗体
severe acute respiratory syndrome coronavirus 2
coronavirus disease 2019
neutral⁃izing antibodies
作者简介
通讯作者:冯健男,E-mail:fengjiannan1970@qq.com,研究员,博士生导师。一直从事计算免疫学与抗体工程研究,特别是在新型抗体分子的合理设计及优化研究方面积累了丰富的经验,主持建立了抗原表位合理预测、抗体专家分析系统和抗体分子合理设计等新技术平台。主持国家和省部级重大和重点课题10余项,获省部级奖励5项,发表SCI论文60余篇,获授权专利10余项。
